Le Lézard
Classified in: Health, Science and technology
Subjects: NPT, PER, SCZ

Buck Institute Names Malene Hansen as Chief Scientific Officer


NOVATO, Calif., Dec. 16, 2020 /PRNewswire/ -- The Buck Institute for Research on Aging is pleased to announce the appointment of Malene Hansen PhD to the position of Professor and Chief Scientific Officer. She will begin her transition to the Buck on February 1, 2021 and fully assume the position effective August 1, 2021.

In this role, and in conjunction with Eric Verdin, MD, Buck President and Chief Executive Officer, Hansen will be responsible for providing leadership and guiding the strategic scientific direction of the Institute. She will also oversee research operations, faculty development, postdoc and student mentoring, and internal and external collaborations in support of this strategy.

"We couldn't be more delighted to welcome Malene to the Buck," says Verdin. "She is an extraordinary scientist with the background, vision, and skills necessary to enhance our leadership position in the field of research on aging and to accelerate our mission. Malene will play a critical role in leading our faculty and in enhancing our postdoctoral and graduate programs. She will also be a critical component of our relationships with academic institutions, biotech and pharmaceutical industry collaborators, and philanthropic supporters."

Hansen comes to the Buck from Sanford Burnham Prebys Medical Discovery Institute where she is a professor in the Development, Aging and Regeneration Program. She is also associate dean of Student Affairs at Sanford Burnham Prebys' Graduate School of Biomedical Sciences, faculty adviser of Postdoctoral Training, and director of the Research and Development Core at San Diego's Nathan Shock Center. Hansen is a global leader in the field of research on aging, and she is currently the chair of the National Institutes of Health's Cellular Mechanisms of Aging and Development Study Section.

Hansen holds a PhD in molecular biology from the University of Copenhagen, and completed additional training at the University of North Carolina and Scripps Research. Prior to joining Sanford Burnham Prebys, she completed a postdoctoral fellowship in molecular genetics in the lab of Cynthia Kenyon PhD, while at the University of California, San Francisco.

"I am truly excited to join the Buck, not only because our field is at an inflection point for breakthrough discoveries that may help extend healthspan, but especially because I look forward to working with the terrific team of scientists and leadership there," says Hansen. Her lab works to understand the molecular mechanisms that affect the process of aging using a combination of genetic, cytological and biochemical approaches, with a particular focus on the relationship between the cellular recycling process autophagy and aging.

About the Buck Institute:

The Buck Institute for Research on Aging is dedicated to ending the threat of age-related disease for this and future generations. Globally recognized as the premier aging research institute, the Buck focuses on identifying and disrupting pathways activated by the aging process that trigger the development of many degenerative diseases, including Alzheimer's, Parkinson's, cancer, diabetes,  and cardiovascular disease. Our goal is to help people live better longer.  Learn more at: https://buckinstitute.org

SOURCE Buck Institute For Research On Aging


These press releases may also interest you

at 09:50
Exegenesis Bio, a rapidly growing global genetic medicines company, is pleased to announce the presentation of clinical efficacy and safety data from its EXG001-307 Phase 1/2 clinical trial in Spinal Muscular Atrophy (SMA) Type I at the American...

at 09:47
BioAro, a pioneer in genomic research and technology, is set to officially launch PanOmiQ, a revolutionary software that will redefine the landscape of genomic analysis globally by providing real-time insights into the complexities of the human...

at 09:45
Pleio, Inc. and FountainRx announce their partnership to provide a concierge-level experience to specialty pharmacy patients. The two companies are launching a program to provide patients with human-driven support as they onboard onto their specialty...

at 09:45
JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today released a Virtual Investor "What This Means" segment featuring Moleculin Biotech , a clinical stage pharmaceutical company with a...

at 09:41
Hyundai Bioscience announced on April 25th that, after multiple consultations with global clinical research organizations (CRO), it has decided to conduct clinical trials for its 'niclosamide-based Dengue antiviral' in...

at 09:35
Inocras, a leading AI-driven whole genome testing company, proudly announces the launch of CancerVision and RareVision, its flagship whole genome diagnostics solutions in solid tumor cancer and rare disease, respectively. CancerVision and...



News published on and distributed by: